Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

COPD: Update Bulletin [July 2017]

Product Code:
596200921
Publication Date:
July 2017
Format:
PDF
Price:
€975

Gain new key opinion leader (KOL) insights on the latest events happening in COPD.

Topics covered include expert opinions on Sunovion’s SUN-101 (glycopyrrolate), delivered via PARI's investigational eFlow nebuliser system. The KOLs also imparted their expectations for the US launch of a generic version of GlaxoSmithKline’s Advair Diskus following the acceptance of Sandoz’s Abbreviated New Drug Application (ANDA) for its fluticasone propionate/salmeterol combination product. Finally, the experts shared their views on the updated National Institute for Health and Care Excellence (NICE) recommendations for AstraZeneca’s oral phosphodiesterase type 4 (PDE4) inhibitor Daxas (roflumilast).

Business Questions:

  • What are the KOLs’ opinions on SUN-101/eFlow’s delivery system?
  • How do experts anticipate SUN-101/eFlow will be differentiated from marketed long‑acting muscarinic antagonist (LAMAs)? 
  • In which patients do KOLs anticipate SUN-101/eFlow will be most frequently prescribed?
  • What are KOL expectations for generic versions of GSK’s Advair?
  • What impact will the launch of generic versions of Advair have on prescribing of originator products?
  • Do the experts have any reservations about prescribing generic versions of Advair?
  • How do experts view the updated NICE recommendations for roflumilast?
  • What impact will the updated NICE recommendations have on prescribing of roflumilast?
  • What concerns do the experts have regarding the use of roflumilast?



customer.service@firstwordpharma.com

All Contents Copyright © 2017 Doctor's Guide Publishing Limited All Rights Reserved